Online citations, reference lists, and bibliographies.
← Back to Search

ERS/ESTS/EACTS/ESTRO Guidelines For The Management Of Malignant Pleural Mesothelioma

A. Scherpereel, I. Opitz, T. Berghmans, I. Psallidas, M. Glatzer, D. Rigau, P. Astoul, S. Boeluekbas, Jeanette Boyd, J. Coolen, Charlotte De Bondt, D. D. De Ruysscher, V. Durieux, C. Faivre-Finn, D. Fennell, F. Galateau‐Sallé, L. Greillier, M. A. Hoda, W. Klepetko, A. Lacourt, Phil McElnay, N. Maskell, Luciano Mutti, J. Pairon, P. V. Van Schil, J. Van Meerbeeck, D. Waller, W. Weder, G. Cardillo, P. M. Putora
Published 2020 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The European Respiratory Society (ERS)/European Society of Thoracic Surgeons (ESTS)/European Association for Cardio-Thoracic Surgery (EACTS)/European Society for Radiotherapy and Oncology (ESTRO) task force brought together experts to update previous 2009 ERS/ESTS guidelines on management of malignant pleural mesothelioma (MPM), a rare cancer with globally poor outcome, after a systematic review of the 2009–2018 literature. The evidence was appraised using the Grading of Recommendations, Assessment, Development and Evaluation approach. The evidence syntheses were discussed and recommendations formulated by this multidisciplinary group of experts. Diagnosis: pleural biopsies remain the gold standard to confirm the diagnosis, usually obtained by thoracoscopy but occasionally via image-guided percutaneous needle biopsy in cases of pleural symphysis or poor performance status. Pathology: standard staining procedures are insufficient in ∼10% of cases, justifying the use of specific markers, including BAP-1 and CDKN2A (p16) for the separation of atypical mesothelial proliferation from MPM. Staging: in the absence of a uniform, robust and validated staging system, we advise using the most recent 2016 8th TNM (tumour, node, metastasis) classification, with an algorithm for pre-therapeutic assessment. Monitoring: patient's performance status, histological subtype and tumour volume are the main prognostic factors of clinical importance in routine MPM management. Other potential parameters should be recorded at baseline and reported in clinical trials. Treatment: (chemo)therapy has limited efficacy in MPM patients and only selected patients are candidates for radical surgery. New promising targeted therapies, immunotherapies and strategies have been reviewed. Because of limited data on the best combination treatment, we emphasise that patients who are considered candidates for a multimodal approach, including radical surgery, should be treated as part of clinical trials in MPM-dedicated centres. A European expert task force proposes updated and practical guidelines on routine management of malignant pleural mesothelioma, after a systematic review of the 2009–2018 literature (GRADE), including new promising therapies and strategies http://bit.ly/38876ta
This paper references
10.1038/sj.bjc.6690105
The European mesothelioma epidemic
J. Peto (1999)
10.1016/j.canep.2014.02.014
Familial malignant mesothelioma: a population-based study in central Italy (1980-2012).
V. Ascoli (2014)
10.1038/nrc3459
BAP1 and cancer
M. Carbone (2013)
10.1136/oem.2009.048629
Surveillance of mesothelioma and workers' compensation in British Columbia, Canada
Tracy L Kirkham (2010)
Nintedanib in combination with pemetrexed/cisplatin for (chemo
GV Scagliotti (2010)
Overall evaluations of carcinogenicity: an updating of IARC Monographs volumes 1 to 42.
(1987)
Prophylactic irradiation of tracts in patients with pleural mesothelioma: an open-label, multicentre, phase III randomized trial
N Bayman (2019)
10.1016/j.lungcan.2018.10.009
Real-life treatment practice for malignant pleural mesothelioma in Belgium.
M. Rosskamp (2018)
10.1007/s00520-018-4357-0
“It sort of hit me like a baseball bat between the eyes”: a qualitative study of the psychosocial experiences of mesothelioma patients and carers
S. Girgis (2018)
10.1016/S2213-2600(15)00092-2
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.
L. Calabrò (2015)
10.1097/JTO.0000000000000064
Does Surgery Improve Survival of Patients with Malignant Pleural Mesothelioma?: A Multicenter Retrospective Analysis of 1365 Consecutive Patients
P. Bovolato (2014)
10.1097/JTO.0b013e3182572e83
Increased Circulating miR-625-3p: A Potential Biomarker for Patients With Malignant Pleural Mesothelioma
M. Kirschner (2012)
10.1080/08958378.2017.1394931
A 30-year mortality and respiratory morbidity study of refractory ceramic fiber workers
G. Lemasters (2017)
10.1158/1078-0432.CCR-06-0472
Megakaryocyte Potentiation Factor Cleaved from Mesothelin Precursor Is a Useful Tumor Marker in the Serum of Patients with Mesothelioma
M. Onda (2006)
Phase II study of dasatinib in patients with previously treated malignant
AZ Dudek (2012)
platinum-containing (chemo)therapy
P Wheatley-Price (2013)
patients with advanced malignant pleural mesothelioma: phase II trial
EE Habib (2012)
Incidence and survival trends for malignant pleural and peritoneal mesothelioma
M J Soeberg (1982)
10.1183/13993003.01254-2018
Investigating unilateral pleural effusions: the role of cytology
D. Arnold (2018)
10.1038/jes.2012.63
Impacts of land use on spatial distribution of mortality rates of cancers caused by naturally occurring asbestos
Binggan Wei (2012)
10.1002/ajim.22103
All-cause mortality and cancer incidence among adults exposed to blue asbestos during childhood.
A. Reid (2013)
10.1136/oemed-2014-102297
Malignant mesothelioma due to non-occupational asbestos exposure from the Italian national surveillance system (ReNaM): epidemiology and public health issues
A. Marinaccio (2015)
Phase II study of asparagine-glycine-arginine-human tumor necrosis factor α, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma
V Gregorc (2010)
10.1016/S0140-6736(03)13079-6
Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trial
N. Maskell (2003)
10.1016/j.jtho.2017.02.013
The Immune Microenvironment, Genome‐wide Copy Number Aberrations, and Survival in Mesothelioma
B. Thapa (2017)
10.1002/ajim.21015
Pleural mesothelioma mortality and asbestos exposure mapping in Italy.
L. Fazzo (2012)
10.18632/oncotarget.12408
Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers
I. Bononi (2016)
10.1183/09031936.00037310
Valproate–doxorubicin: promising therapy for progressing mesothelioma. A phase II study
A. Scherpereel (2010)
10.1097/JTO.0000000000000499
Is Radiotherapy Useful for Treating Pain in Mesothelioma?: A Phase II Trial
N. Macleod (2015)
10.1136/oemed-2013-101957
High incidence of lung cancer and malignant mesothelioma linked to erionite fibre exposure in a rural community in Central Mexico
M. A. Ortega-Guerrero (2014)
10.1002/ajim.22442
Incidence of malignant mesothelioma of the pleura in Québec and Canada from 1984 to 2007, and projections from 2008 to 2032.
Alfreda Krupoves (2015)
10.3978/j.issn.2225-319X.2012.10.06
Video-atlas of radical pleurectomy for malignant pleural mesothelioma.
S. Boeluekbas (2012)
10.1158/1055-9965.EPI-10-0346
Serum Mesothelin for Early Detection of Asbestos-Induced Cancer Malignant Mesothelioma
J. Creaney (2010)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
WHO Classification Tumours of the Lung and Pleura
WD Travis (2015)
Tumours of the pleura.
G. Hillerdal (1999)
10.1016/j.lungcan.2008.04.001
The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.
J. Stebbing (2009)
Incidence of malignant mesothelioma in New Zealand and Australia: a global snapshot.
Soberg Mj (2015)
10.1038/jes.2009.56
Assessment of cancer risks due to environmental exposure to asbestos
Hermen A L Driece (2010)
10.1097/JTO.0000000000000078
A Feasibility Study Evaluating Surgery for Mesothelioma After Radiation Therapy: The “SMART” Approach for Resectable Malignant Pleural Mesothelioma
B. Cho (2014)
10.1200/JCO.2018.36.15_SUPPL.8503
DREAM: A phase II study of durvalumab with first line chemotherapy in mesothelioma—First results.
A. Nowak (2018)
10.1159/000355687
Is Soluble Mesothelin-Related Protein an Upfront Predictive Marker of Pleural Mesothelioma? A Prospective Study on Italian Workers Exposed to Asbestos
R. Filiberti (2013)
Novel medical therapies for malignant pleural mesothelioma: a review
A Scherpereel (2018)
Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing (chemo)therapy
S Papa (2013)
Trends and patterns of disparities in cancer mortality among US counties
A H Mokdad (1980)
10.1016/j.lungcan.2013.04.018
A genome-wide association study for malignant mesothelioma risk.
G. Cadby (2013)
10.1200/JCO.2018.79.0543
Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.
D. Fennell (2019)
10.1016/j.ijrobp.2015.06.029
Radical Radiation Therapy After Lung-Sparing Surgery for Malignant Pleural Mesothelioma: Survival, Pattern of Failure, and Prognostic Factors.
E. Minatel (2015)
10.1016/j.lungcan.2012.06.011
Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium.
N. Campbell (2012)
10.1016/j.athoracsur.2017.09.036
National Trends in the Epidemiology of Malignant Pleural Mesothelioma: A National Cancer Data Base Study.
Sahar A Saddoughi (2018)
10.3816/CLC.2010.n.005
Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study.
N. Katirtzoglou (2010)
10.1002/ajim.22065
A decade of malignant mesothelioma surveillance in Korea.
Soon-Hee Jung (2012)
10.1097/SLA.0000000000000903
Extrapleural Pneumonectomy in the Treatment of Epithelioid Malignant Pleural Mesothelioma: Novel Prognostic Implications of Combined N1 and N2 Nodal Involvement Based on Experience in 529 Patients
D. Sugarbaker (2014)
10.1183/13993003.00091-2016
Incidence and familial risk of pleural mesothelioma in Sweden: a national cohort study
J. Ji (2016)
10.1097/JTO.0b013e31828c2b26
Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy
S. Papa (2013)
10.1200/JCO.1998.16.1.145
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
10.1378/CHEST.108.3.754
Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy.
C. Boutin (1995)
10.1126/science.aaa1348
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
N. Rizvi (2015)
10.1055/S-2007-1012685
Invasive Procedures in the Diagnosis of Pleural Disease
J. R. Tomlinson (1987)
10.1007/s00420-013-0853-1
Changes of mesothelin and osteopontin levels over time in formerly asbestos-exposed power industry workers
M. K. Felten (2013)
10.1001/JAMA.1997.03550020100049
Evidence-based Medicine: How to Practice and Teach EBM
S. Satyamurti (1997)
[Surgery for malignant pleural mesothelioma].
R. Giudicelli (2004)
ESTS textbook of thoracic surgery
J. Kużdżał (2014)
10.1111/cas.12954
Multiwalled carbon nanotubes intratracheally instilled into the rat lung induce development of pleural malignant mesothelioma and lung tumors
M. Suzui (2016)
10.1016/j.jtho.2016.09.123
The IASLC Mesothelioma Staging Project: Improving Staging of a Rare Disease Through International Participation
H. Pass (2016)
10.1016/j.athoracsur.2016.06.069
A Multicenter Study of Volumetric Computed Tomography for Staging Malignant Pleural Mesothelioma.
V. Rusch (2016)
10.1200/JCO.2018.36.15_SUPPL.8504
Inherited predisposition to malignant mesothelioma (MM) due to mutations in DNA repair genes.
R. Hassan (2018)
10.1097/JTO.0b013e318275b346
Incidence and Survival of Malignant Pleural Mesothelioma in Norway: A Population-Based Study of 1686 Cases
Å. Helland (2012)
10.1016/j.radonc.2018.01.003
Update of the systematic review of palliative radiation therapy fractionation for bone metastases.
S. Rich (2018)
10.1016/S1470-2045(11)70149-8
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
10.1056/NEJMRA050152
Advances in malignant mesothelioma.
B. Robinson (2005)
A phase II clinical trial of the vascular disrupting agent BNC105P
AK Nowak (2012)
10.2471/BLT.11.086678
Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008.
V. Delgermaa (2011)
10.1111/risa.12887
Ambient Asbestos Fiber Concentrations and Long-Term Trends in Pleural Mesothelioma Incidence between Urban and Rural Areas in the United States (1973-2012).
M. E. Glynn (2018)
10.1016/j.envint.2014.10.016
Impact of an asbestos cement factory on mesothelioma incidence: global assessment of effects of occupational, familial, and environmental exposure.
C. Mensi (2015)
Pleurectomy/decortication for the treatment of malignant pleural mesothelioma
S Bölükbas (2014)
10.1016/S0140-6736(15)01238-6
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
G. Zalcman (2016)
10.1111/1753-6405.12503
Patterns in the incidence, mortality and survival of malignant pleural and peritoneal mesothelioma, New South Wales, 1972–2009
M. Soeberg (2016)
10.1164/rccm.200802-258OC
Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study.
E. Park (2008)
10.21037/atm.2017.06.60
Diagnosis and prognosis-review of biomarkers for mesothelioma.
H. H. Sun (2017)
10.1038/nm.3947
Loss of BAP1 function leads to EZH2-dependent transformation
Lindsay M. LaFave (2015)
10.1016/S1470-2045(15)00208-9
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.
R. Stahel (2015)
10.5090/kjtcs.2014.47.2.124
Is There a Role for a Needle Thoracoscopic Pleural Biopsy under Local Anesthesia for Pleural Effusions?
H. Son (2014)
10.1002/ijc.24711
Evolution of pleural cancers and malignant pleural mesothelioma incidence in France between 1980 and 2005
N. Le Stang (2010)
10.1016/j.jtho.2016.09.121
The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma
D. Rice (2016)
10.17061/phrp2641646
Mesothelioma trends in the ACT and comparisons with the rest of Australia.
R. Korda (2016)
10.1200/JCO.2011.41.5869
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
H. Kindler (2012)
10.1007/s00408-016-9868-1
Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure
Melike Demir (2016)
10.1038/sj.bjc.6601957
A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma
S. Bydder (2004)
10.1200/JCO.18.01678
Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial.
N. Bayman (2019)
10.1007/s12199-015-0501-3
High-risk mesothelioma relation to meteorological and geological condition and distance from naturally occurring asbestos
A. Abakay (2015)
10.1007/s10552-014-0368-4
Regional variations in German mesothelioma mortality rates: 2000–2010
S. Schonfeld (2014)
WHO Classification Tumours of the Lung and Pleura. 4th Edn
W D Travis (2015)
10.1097/JOM.0b013e3181b68cef
Risk of Mesothelioma and Occupational Exposure to Asbestos and Man-Made Vitreous Fibers: Evidence From Two Case-Control Studies in Montreal, Canada
J. Pintos (2009)
10.2214/AJR.09.3519
Diffusion-weighted MRI of malignant pleural mesothelioma: preliminary assessment of apparent diffusion coefficient in histologic subtypes.
R. Gill (2010)
10.1097/JTO.0b013e3182208e3f
Recommendations for Uniform Definitions of Surgical Techniques for Malignant Pleural Mesothelioma: A Consensus Report of the International Association for the Study of Lung Cancer International Staging Committee and the International Mesothelioma Interest Group
D. Rice (2011)
10.1371/journal.pone.0061253
Genetic Variants Associated with Increased Risk of Malignant Pleural Mesothelioma: A Genome-Wide Association Study
G. Matullo (2013)
10.1016/S1470-2045(17)30446-1
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
M. Maio (2017)
10.1111/cas.12687
Chemokine (C-C motif) ligand 3 detection in the serum of persons exposed to asbestos: A patient-based study
J. Xu (2015)
10.1016/j.jtho.2015.12.108
A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma Using Decision Tree Analysis
F. Brims (2016)
malignant pleural mesothelioma: a single institution study
L Calabrò (2011)
10.1186/s12885-017-3375-5
Calretinin as a blood-based biomarker for mesothelioma
G. Johnen (2017)
10.3390/ijerph10115629
Domestic Asbestos Exposure: A Review of Epidemiologic and Exposure Data
E. Goswami (2013)
10.1002/ijc.26229
Pleural malignant mesothelioma epidemic: Incidence, modalities of asbestos exposure and occupations involved from the Italian National Register
A. Marinaccio (2012)
10.21037/tlcr.2018.10.02
Combined modality treatment in mesothelioma: a systemic literature review with treatment recommendations.
Charlotte De Bondt (2018)
10.1016/S0140-6736(03)14794-0
Mesothelin-family proteins and diagnosis of mesothelioma
B. Robinson (2003)
10.1371/journal.pone.0046091
Early Detection of Malignant Pleural Mesothelioma in Asbestos-Exposed Individuals with a Noninvasive Proteomics-Based Surveillance Tool
R. Ostroff (2012)
10.1080/10937404.2016.1193361
Five years update on relationships between malignant pleural mesothelioma and exposure to asbestos and other elongated mineral particles
P. Andujar (2016)
10.1016/j.jtho.2019.08.2506
EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach.
A. Nicholson (2019)
10.1016/S1470-2045(18)30765-4
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
A. Scherpereel (2019)
comparing two popular (chemo)therapy regimens
N Katirtzoglou (2013)
10.6004/JNCCN.2012.0006
[Malignant pleural mesothelioma].
Q. Kong (1983)
10.1093/mutage/get008
Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma.
P. Andujar (2013)
10.1007/s11864-019-0613-x
Use of Immune Checkpoint Inhibitors in Mesothelioma
P. Forde (2019)
10.1200/JCO.2018.78.5204
Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma.
V. Panou (2018)
10.1186/s13027-015-0022-0
NLRP1 and NLRP3 polymorphisms in mesothelioma patients and asbestos exposed individuals a population-based autopsy study from North East Italy
V. Borelli (2015)
10.1200/JCO.2016.71.3230
Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1–Deficient Thoracic Cancers
E. Beddowes (2017)
10.4415/ANN_14_02_04
Health impact of the exposure to fibres with fluoro-edenitic composition on the residents in Biancavilla (Sicily, Italy): mortality and hospitalization from current data.
S. Conti (2014)
10.1016/j.jtho.2017.04.002
Epidemiology of Environmental Exposure and Malignant Mesothelioma.
Bian Liu (2017)
10.1056/NEJMoa1115050
Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.
H. Pass (2012)
10.1038/bjc.2013.368
Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma
G. Ceresoli (2013)
10.1183/16000617.0063-2016
Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment
A. Bibby (2016)
10.1016/J.JTCVS.2004.10.034
Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications.
J. Erasmus (2005)
10.1136/oemed-2016-104002
Response to: ‘Pleural mesothelioma and occupational and non-occupational asbestos exposure: a case-control study with quantitative risk assessment’ by Ferrante et al
G. Marsh (2016)
10.1016/S0140-6736(58)91439-9
Pleural biopsy in the diagnosis of pleural effusion; a report of 200 cases.
P. Mestitz (1958)
10.1097/JTO.0000000000000360
SWOG S0722: Phase II Study of mTOR Inhibitor Everolimus (RAD001) in Advanced Malignant Pleural Mesothelioma (MPM)
S. Ou (2015)
10.1183/09031936.00079407
Drain site radiotherapy in malignant pleural mesothelioma: a wasted resource
R. Muirhead (2007)
10.1002/cam4.656
Radiation‐induced mesothelioma among long‐term solid cancer survivors: a longitudinal analysis of SEER database
A. Farioli (2016)
10.1016/j.athoracsur.2009.05.022
Endoscopic ultrasound-guided fine needle aspiration for staging of malignant pleural mesothelioma.
D. Rice (2009)
10.1016/j.prro.2016.08.001
Palliative radiation therapy for bone metastases: Update of an ASTRO Evidence-Based Guideline.
S. Lutz (2017)
10.1378/chest.08-1345
American College of Chest Physicians consensus statement on the respiratory health effects of asbestos. Results of a Delphi study.
D. Banks (2009)
10.1177/1403494815596500
Emerging evidence that the ban on asbestos use is reducing the occurrence of pleural mesothelioma in Sweden
B. Järvholm (2015)
Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma: a phase II study
M Disselhorst (2019)
10.1097/CEJ.0000000000000384
Time trends and spatial patterns in the mesothelioma incidence in Slovenia, 1961–2014
V. Zadnik (2017)
10.1016/j.thorsurg.2012.10.002
Surgical management of malignant pleural mesothelioma.
J. Yanagawa (2013)
10.1016/j.humpath.2017.07.015
The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center.
A. Marchevsky (2017)
10.1007/978-3-642-16483-5_3107
International Agency for Research on Cancer.
E. Somers (1985)
10.1016/S1470-2045(18)30100-1
Novel therapies for malignant pleural mesothelioma.
A. Scherpereel (2018)
10.1016/S1470-2045(18)30294-8
Development and validation of response markers to predict survival and pleurodesis success in patients with malignant pleural effusion (PROMISE): a multicohort analysis.
I. Psallidas (2018)
10.1136/thoraxjnl-2014-205205
Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma
J. Creaney (2014)
10.1510/icvts.2009.213611
Staging algorithm for diffuse malignant pleural mesothelioma.
M. Zieliński (2010)
10.1016/S2213-2600(18)30151-6
Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.
L. Calabrò (2018)
10.1016/0003-9969(77)90111-X
Effects of x-irradiation and the resultant inanition on amylase content of the rat parotid gland.
M. Sodicoff (1977)
10.21037/tlcr.2017.05.03
BAP1, a tumor suppressor gene driving malignant mesothelioma.
M. Cheung (2017)
10.1080/19338240903390305
Endemic Malignant Mesothelioma: Exposure to Erionite Is More Important Than Genetic Factors
M. Metintas (2010)
10.1016/j.canep.2015.08.007
The next mesothelioma wave: mortality trends and forecast to 2030 in Brazil.
E. Algranti (2015)
10.1016/j.cell.2015.09.001
Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity
A. Serrels (2015)
10.1111/j.1445-2197.2009.05060.x
Bilateral thoracoscopy, mediastinoscopy and laparoscopy, in addition to CT, MRI and PET imaging, are essential to correctly stage and treat patients with mesothelioma prior to trimodality therapy *
J. Alvarez (2009)
Efficacy and safety of an intensified schedule of tremelimumab for (chemo) therapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study
L Calabrò (2015)
Phase II study of pemetrexed and carboplatin plus bevacizumab
GL Ceresoli (2016)
malignant pleural mesothelioma: a phase II study
V Kovac (2010)
Leukemia Group B (CALGB 30107)
LM Krug (2012)
10.1159/000080638
Safety and Yield of Ultrasound-Assisted Transthoracic Biopsy Performed by Pulmonologists
A. Diacon (2004)
10.1016/j.rmed.2009.05.017
Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis.
Ling Luo (2010)
10.1097/JOM.0b013e3181dc6d45
Vermiculite Worker Mortality: Estimated Effects of Occupational Exposure to Libby Amphibole
Theodore C. Larson (2010)
10.1136/oemed-2012-101198
Pleural mesothelioma in relation to meteorological conditions and residential distance from an industrial source of asbestos
J. Tarrés (2013)
10.5301/tj.5000559
Data Quality in Rare Cancers Registration: The Report of the RARECARE Data Quality Study
A. Trama (2017)
10.1097/JTO.0b013e31823e0667
Pleural Fluid Cytological Yield and Visceral Pleural Invasion in Patients with Epithelioid Malignant Pleural Mesothelioma
V. Pinelli (2012)
10.1038/nature22798
BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation
A. Bononi (2017)
10.1136/oem.2009.047019
Non-occupational exposure to asbestos and malignant mesothelioma in the Italian National Registry of Mesotheliomas
D. Mirabelli (2010)
10.4415/ANN_14_02_02
Incidence of pleural mesothelioma in a community exposed to fibres with fluoro-edenitic composition in Biancavilla (Sicily, Italy).
C. Bruno (2014)
10.1038/ng.912
Germline BAP1 mutations predispose to malignant mesothelioma
J. Testa (2011)
Tremelimumab for patients with (chemo)therapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial
L Calabrò (2013)
CBP501 in patients with advanced malignant pleural mesothelioma
ME O’Brien (2014)
10.1016/j.mrfmmm.2011.01.001
XRCC1 and ERCC1 variants modify malignant mesothelioma risk: a case-control study.
M. Betti (2011)
10.1136/oemed-2017-104298
Estimation of the global burden of mesothelioma deaths from incomplete national mortality data
Chimed-Ochir Odgerel (2017)
10.1200/JCO.2013.31.15_SUPPL.E18544
Clinical characteristics, treatment and survival outcomes in malignant pleural mesothelioma: an institutional experience in Turkey.
M. Kuçukoner (2014)
10.1289/ehp.1002862
Pleural Mesothelioma in New Caledonia: Associations with Environmental Risk Factors
F. Baumann (2011)
10.1155/2017/5756102
Serum HMGB1 as a Potential Biomarker for Patients with Asbestos-Related Diseases
Shibo Ying (2017)
10.1186/1471-2407-13-528
Pleural cancer mortality in Spain: time-trends and updating of predictions up to 2020
G. López-Abente (2013)
10.1179/2049396714Y.0000000058
Asbestos in Belgium: an underestimated health risk. The evolution of mesothelioma mortality rates (1969–2009)
Laura Van den Borre (2014)
10.1016/J.EJCTS.2003.12.001
The case for routine cervical mediastinoscopy prior to radical surgery for malignant pleural mesothelioma.
J. Pilling (2004)
10.1158/1078-0432.CCR-06-1101
In vivo Loss of Expression of Argininosuccinate Synthetase in Malignant Pleural Mesothelioma Is a Biomarker for Susceptibility to Arginine Depletion
P. Szlosarek (2006)
10.1016/S0169-5002(16)30212-4
195 A feasibility study comparing (extended) pleurectomy decortication versus no pleurectomy decortication in the multimodality management of patients with malignant pleural mesothelioma: the MARS 2 study
E. Lim (2016)
10.1002/1097-0274(200103)39:3<262::AID-AJIM1014>3.0.CO;2-R
Asbestos and man-made vitreous fibers as risk factors for diffuse malignant mesothelioma: results from a German hospital-based case-control study.
K. Rödelsperger (2001)
10.3892/MCO.2013.197
Retrospective analysis of large-scale research screening of construction workers for the early diagnosis of mesothelioma.
T. Hirohashi (2014)
10.1016/j.ejca.2013.05.008
Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).
M. O'Brien (2013)
10.1200/JCO.2017.73.8401
Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching Analysis.
D. Nelson (2017)
10.4415/ANN_14_04_05
Mesothelioma incidence in the neighbourhood of an asbestos-cement plant located in a national priority contaminated site.
L. Fazzo (2014)
10.2471/BLT.13.132118
Asbestos: use, bans and disease burden in Europe
T. Kameda (2014)
10.1136/oem.2010.062182
Trends in mesothelioma mortality rates in South Africa: 1995–2007
D. Kielkowski (2011)
10.1245/s10434-010-1107-z
Volume-Based Parameter of 18F-FDG PET/CT in Malignant Pleural Mesothelioma: Prediction of Therapeutic Response and Prognostic Implications
H. Lee (2010)
randomised, placebo-controlled phase 3 trial
F Grosso (2019)
10.1007/s10653-013-9578-z
Environmental occurrence, origin, physical and geochemical properties, and carcinogenic potential of erionite near San Miguel de Allende, Mexico
M. A. Ortega-Guerrero (2013)
placebo-controlled trial
J Stebbing (2015)
for second line therapy of advanced malignant pleural mesothelioma
A Scherpereel (2009)
10.1186/s12014-016-9103-3
ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms
D. Morré (2016)
10.1136/oemed-2015-102803
Pleural mesothelioma and occupational and non-occupational asbestos exposure: a case-control study with quantitative risk assessment
D. Ferrante (2015)
10.1136/oemed-2013-102000
Mortality experience among Minnesota taconite mining industry workers
Elizabeth M. Allen (2014)
10.1016/J.JTCVS.2005.11.044
The pattern of lymph node involvement influences outcome after extrapleural pneumonectomy for malignant mesothelioma.
J. Edwards (2006)
10.1038/sj.bjc.6605637
Occupation and cancer in Britain
L. Rushton (2010)
10.1097/JTO.0000000000000661
A New Prognostic Score Supporting Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma: A Review of 12 Years’ Experience
I. Opitz (2015)
10.1001/ARCHINTE.1984.00350140139020
Sensitivity, specificity, and predictive values of closed pleural biopsy.
R. H. Poe (1984)
10.1016/j.cca.2014.02.024
Diagnostic accuracy of osteopontin for malignant pleural mesothelioma: a systematic review and meta-analysis.
Z. Hu (2014)
10.1158/1078-0432.CCR-14-0804
Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
R. Hassan (2014)
10.1016/j.lungcan.2014.06.008
Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma.
L. Krug (2014)
10.4103/0019-5278.146897
Global mesothelioma epidemic: Trend and features
C. Bianchi (2014)
10.1002/cncr.23034
Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesothelioma
L. Greillier (2007)
10.1097/JOM.0b013e318250b5f5
Mesothelioma Associated With Commercial Use of Vermiculite Containing Libby Amphibole
Kari K. Dunning (2012)
10.21037/tlcr.2017.05.06
Diagnostic and prognostic biomarkers for malignant mesothelioma: an update.
Z. Chen (2017)
Malignant pleural mesothelioma incidence and survival in the Republic of Ireland
C J Jennings (1994)
10.1002/14651858.CD012605.pub2
Radical multimodality therapy for malignant pleural mesothelioma.
O. Abdel-Rahman (2018)
10.1038/nrc.2017.42
Novel insights into mesothelioma biology and implications for therapy
T. Yap (2017)
10.1097/JTO.0b013e318248242c
Phase II Study of Dasatinib in Patients with Previously Treated Malignant Mesothelioma (Cancer and Leukemia Group B 30601): A Brief Report
A. Dudek (2012)
10.1136/oem.2009.050336
Possible effect of environmental exposure to asbestos on geographical variation in mesothelioma rates
S. Goldberg (2010)
10.1038/ng.3520
Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations
R. Bueno (2016)
10.1016/j.lungcan.2018.07.007
Current efforts in research of pleural mesothelioma-An analysis of the ClinicalTrials.gov registry.
Krisztian Süveg (2018)
10.21147/j.issn.1000-9604.2017.04.09
Epidemiology and trend analysis on malignant mesothelioma in China
J. Zhao (2017)
10.1200/JCO.2017.76.6394
Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.
H. Kindler (2018)
10.1136/oemed-2015-103309
Incidence and survival trends for malignant pleural and peritoneal mesothelioma, Australia, 1982–2009
M. Soeberg (2016)
10.1002/ajim.22063
Malignant mesothelioma incidence among talc miners and millers in New York State.
M. Finkelstein (2012)
10.1080/09603123.2012.733938
Cancer morbidity of residents living near an oil refinery plant in North-West Italy
C. Salerno (2013)
10.1097/LBR.0000000000000145
Role of Medical Thoracoscopy and Closed-Blind Pleural Biopsy in Undiagnosed Exudative Pleural Effusions: A Single-Center Experience of 348 Patients
V. N. Maturu (2015)
mesothelioma. A phase II study
LM Krug (2011)
A phase II clinical trial of the vascular disrupting agent BNC105P as second line (chemo)therapy for advanced Malignant Pleural Mesothelioma
A K Nowak (2013)
mesothelioma: a single institution phase II study
Ó Arrieta (2009)
10.1002/ijc.27758
Familial aggregation of malignant mesothelioma in former workers and residents of Wittenoom, Western Australia
N. de Klerk (2013)
Incidence of malignant mesothelioma in New Zealand and Australia: a global snapshot.
Matthew J Soberg (2015)
10.1016/S2213-2600(18)30420-X
Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.
M. Disselhorst (2019)
10.1002/ajim.22106
Compensation of pleural mesothelioma in France: data from the French National Mesothelioma Surveillance Programme.
S. Chamming’s (2013)
10.1186/s12995-016-0127-4
Malignant mesothelioma incidence by nation-wide cancer registry: a population-based study
K. Tomasson (2016)
10.1186/s12885-015-1301-2
Epidemiological patterns of asbestos exposure and spatial clusters of incident cases of malignant mesothelioma from the Italian national registry
M. Corfiati (2015)
10.1007/s00408-013-9526-9
Serum Biomarkers in Patients with Mesothelioma and Pleural Plaques and Healthy Subjects Exposed to Naturally Occurring Asbestos
Mehmet Bayram (2013)
10.1001/jamaoncol.2016.3049
Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1–Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial
P. Szlosarek (2017)
10.1158/1078-0432.CCR-15-1130
HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients
A. Napolitano (2016)
10.5858/arpa.2015-0508-LE
Immunohistochemistry for NF2, LATS1/2, and YAP/TAZ Fails to Separate Benign From Malignant Mesothelial Proliferations.
B. Sheffield (2016)
10.1007/s10653-013-9518-y
The assessment of the malignant mesothelioma cases and environmental asbestos exposure in Sivas province, Turkey
S. Berk (2013)
Malignant Pleural Mesothelioma Guidelines Version 2
(2018)
10.1097/JTO.0b013e3181ec18db
A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307
S. Dubey (2010)
10.1016/S0140-6736(59)90032-7
PLEURAL BIOPSY IN THE DIAGNOSIS OF PLEURAL EFFUSION
A. Karlish (1959)
10.1016/j.lungcan.2012.05.111
A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma.
J. Dowell (2012)
10.1016/S0140-6736(14)60418-9
Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial
R. Rintoul (2014)
10.3109/08958378.2012.683892
Are airborne refractory ceramic fibers similar to asbestos in their carcinogenicity?
A. Walker (2012)
10.1016/j.lungcan.2015.06.018
Second line therapy in malignant pleural mesothelioma: A systematic review.
W. Buikhuisen (2015)
10.1002/ajim.20780
Case-control study of pleural mesothelioma in workers with social security in Mexico.
G. Aguilar-Madrid (2010)
10.1093/ejcts/ezv422
Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma.
Diana Y. Kircheva (2016)
10.1183/09059180.00007014
Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic
O. D. Røe (2015)
10.1183/13993003.00349-2018
ERS/EACTS statement on the management of malignant pleural effusions
A. Bibby (2018)
10.1378/CHEST.120.6.1798
Percutaneous image-guided cutting needle biopsy of the pleura in the diagnosis of malignant mesothelioma.
R. F. Adams (2001)
10.1183/09031936.00226111
Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma
I. Pantazopoulos (2012)
cisplatin for malignant pleural mesothelioma
K Kuribayashi (2012)
10.7860/JCDR/2014/7476.4310
Medical Thoracoscopy vs Closed Pleural Biopsy in Pleural Effusions: A Randomized Controlled Study.
N. Haridas (2014)
10.1016/S1470-2045(16)30095-X
Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial
A. Clive (2016)
10.1016/j.jtho.2016.08.147
The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma
A. Nowak (2016)
10.1016/j.canlet.2015.09.011
Germline BAP1 mutation in a family with high incidence of multiple primary cancers and a potential gene-environment interaction.
M. Cheung (2015)
10.1016/j.jtho.2015.10.003
Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma
A. Billè (2016)
10.1038/nm1196
Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy
A. J. Muller (2005)
10.1016/S1470-2045(13)70381-4
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
L. Calabrò (2013)
10.1097/PAS.0000000000000529
Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens
H. Hwang (2016)
Docetaxel plus gemcitabine as first-line treatment in malignant pleural mesothelioma: a single institution phase II study.
M. Ralli (2009)
10.1097/JTO.0b013e31826915f1
Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database
V. Rusch (2012)
10.1038/nature13954
PD-1 blockade induces responses by inhibiting adaptive immune resistance
P. Tumeh (2014)
10.1016/j.cell.2016.08.069
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
J. Gao (2016)
10.1093/carcin/bgu227
Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival.
F. Baumann (2015)
10.1016/J.RADONC.2007.05.022
A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma.
N. O’Rourke (2007)
placebo-controlled phase 2b trial
V Gregorc (2017)
Regional differences in incidence of malignant mesothelioma in Denmark.
E. Skammeritz (2013)
malignant mesothelioma: an open-label, single-arm, phase 2 trial
L Calabrò (2013)
10.1378/chest.14-0299
Physician-based ultrasound-guided biopsy for diagnosing pleural disease.
R. Hallifax (2014)
10.1378/CHEST.113.3.723
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
10.1179/2049396712Y.0000000016
Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003–2008
S. Jane Henley (2013)
10.1093/jnci/djs513
Pleural plaques and the risk of pleural mesothelioma.
J. Pairon (2013)
10.1097/JTO.0b013e318191520c
Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma
S. Ramalingam (2009)
patients with advanced malignant mesothelioma
HL Kindler (2012)
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
NA Rizvi (2015)
[Treatment of malignant pleural mesothelioma].
T. Yusa (2007)
10.2217/bmm.11.18
Soluble markers for diagnosis of malignant pleural mesothelioma.
A. Cristaudo (2011)
10.1073/pnas.1105887108
Erionite exposure in North Dakota and Turkish villages with mesothelioma
M. Carbone (2011)
10.3892/MCO.2013.118
Methotrexate and gemcitabine combination chemotherapy for the treatment of malignant pleural mesothelioma.
K. Kuribayashi (2013)
10.1093/ANNONC/MDJ073
A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial.
M. O'Brien (2006)
10.1093/ejcts/ezx427
Predictors of trimodality therapy and trends in therapy for malignant pleural mesothelioma†
D. Nelson (2018)
10.1007/s10552-016-0838-y
Incidence of malignant mesothelioma in Germany 2009–2013
Martin Lehnert (2016)
of Clinical Oncology clinical practice guideline
H L Kindler (2018)
10.1097/JTO.0b013e318229586e
Phase II Study of Cediranib in Patients with Malignant Pleural Mesothelioma: SWOG S0509
L. Garland (2011)
10.1183/09031936.00017011
Malignant mesothelioma in Metsovo, Greece, from domestic use of asbestos: 30 years later
A. Gogali (2012)
10.1097/JTO.0b013e318260dfb9
Phase II Clinical Trial of First or Second-Line Treatment with Bortezomib in Patients with Malignant Pleural Mesothelioma
D. Fennell (2012)
10.1200/JCO.2016.67.2675
Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma.
A. Rimner (2016)
10.1001/archinte.150.6.1190
Cytologic and bacteriologic analysis of fluid and pleural biopsy specimens with Cope's needle. Study of 414 patients.
C. Escudero Bueno (1990)
10.3390/ijms20020429
BAP1 Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine Treatment
A. Guazzelli (2019)
10.1155/2017/9280170
Circulating miR-132-3p as a Candidate Diagnostic Biomarker for Malignant Mesothelioma
D. Weber (2017)
10.1038/ncomms10501
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
S. Koyama (2016)
10.1002/(SICI)1097-0274(199711)32:5<445::AID-AJIM3>3.0.CO;2-R
Pleural plaques as risk indicators for malignant pleural mesothelioma: a necropsy-based study.
C. Bianchi (1997)
10.1136/thoraxjnl-2013-203744
Occupational and non-occupational attributable risk of asbestos exposure for malignant pleural mesothelioma
A. Lacourt (2014)
10.1136/THX.54.3.238
Percutaneous cervical cordotomy for the control of pain in patients with pleural mesothelioma.
M. B. Jackson (1999)
10.1097/JTO.0000000000000181
Supplementary Prognostic Variables for Pleural Mesothelioma
H. Pass (2014)
10.1016/j.lungcan.2018.07.041
Highlights of the 14th international mesothelioma interest group meeting: Pathologic separation of benign from malignant mesothelial proliferations and histologic/molecular analysis of malignant mesothelioma subtypes.
A. Churg (2018)
10.1016/S1470-2045(17)30169-9
Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.
E. Alley (2017)
10.1016/j.lungcan.2015.09.021
Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma.
L. Santarelli (2015)
10.5858/arpa.2017-0124-RA
Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.
A. Husain (2018)
10.1007/s10653-012-9504-9
Geologic occurrences of erionite in the United States: an emerging national public health concern for respiratory disease
Bradley S. Van Gosen (2013)
10.1001/jamaoncol.2016.6770
Effect of Radiotherapy on Painful Bone Metastases: A Secondary Analysis of the NCIC Clinical Trials Group Symptom Control Trial SC.23
Rachel Mcdonald (2017)
10.1001/jama.2016.20324
Trends and Patterns of Disparities in Cancer Mortality Among US Counties, 1980-2014
A. Mokdad (2017)
10.1016/S1470-2045(17)30621-6
Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.
N. van Zandwijk (2017)
10.1200/JCO.2011.39.6671
Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.
Kevin Hollevoet (2012)
10.1016/j.lungcan.2016.01.017
Diagnostic accuracy of sequential co-registered PET+MR in comparison to PET/CT in local thoracic staging of malignant pleural mesothelioma.
K. Martini (2016)
10.1200/JCO.2017.72.9012
Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.
F. Grosso (2017)
10.1093/annonc/mdq173
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
R. Stahel (2010)
WHO classification of tumours of the lung, pleura, thymus and heart
W. Travis (2015)
10.1016/J.JTHO.2017.09.329
OA 02.02 Ipilimumab and Nivolumab in the Treatment of Recurrent Malignant Pleural Mesothelioma: A Phase II Study
M. Disselhorst (2017)
10.13075/ijomeh.1896.00890
Pleural mesothelioma in household members of asbestos-exposed workers in Friuli Venezia Giulia, Italy.
Flavia D' Agostin (2017)
10.1007/s00204-010-0580-2
Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos
M. Gube (2010)
10.1016/j.jtho.2016.01.014
A Randomized Phase II Study Adding Axitinib to Pemetrexed‐Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single‐Center Trial Combining Clinical and Translational Outcomes
W. Buikhuisen (2016)
10.1097/CAD.0b013e32834d7a1c
A phase II trial of low-dose gemcitabine in a prolonged infusion and cisplatin for malignant pleural mesothelioma
V. Kovač (2012)
Combination Immunotherapy Superior to Monotherapy in Patients with Melanoma.
C. Doyle (2015)
10.1002/cncr.24886
Proposed adjustments to pathologic staging of epithelial malignant pleural mesothelioma based on analysis of 354 cases
W. Richards (2010)
10.1002/14651858.CD003880.PUB4
Radiotherapy for malignant pleural mesothelioma.
E. Chapman (2006)
10.3109/08958378.2015.1051640
Are pleural plaques an appropriate endpoint for risk analyses?
L. Maxim (2015)
10.1016/J.EJCDT.2013.08.012
Diagnosis of exudative pleural effusion using ultrasound guided versus medical thoracoscopic pleural biopsy
E. Mohamed (2013)
10.1016/j.ijheh.2013.07.008
Lung cancer and mesothelioma risk assessment for a population environmentally exposed to asbestos.
Marie-Hélène Bourgault (2014)
10.1007/s12094-013-1015-3
Chemotherapy management of malignant pleural mesothelioma: a phase II study comparing two popular chemotherapy regimens
E. Habib (2013)
10.1371/journal.pone.0183404
Estimated future incidence of malignant mesothelioma in South Korea: Projection from 2014 to 2033
K. M. Kwak (2017)
10.1016/j.lungcan.2011.11.014
Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).
T. Jahan (2012)
10.1183/09031936.00063109
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
A. Scherpereel (2009)
10.1016/j.jtho.2016.06.020
BRCA1‐Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: A Large Retrospective Study
L. Righi (2016)
First-line (chemo)therapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial
Ó Arrieta (2012)
10.1136/oemed-2016-103776
Response to: Pleural mesothelioma, and occupational and non-occupational asbestos exposure: a case–control study with quantitative risk assessment.
P. Boffetta (2016)
10.1093/ejcts/ezs521
Serum concentration of integrin-linked kinase in malignant pleural mesothelioma and after asbestos exposure.
S. Watzka (2013)
10.1016/j.scitotenv.2012.02.047
Industrial pollution and pleural cancer mortality in Spain.
G. López-Abente (2012)
10.1136/thoraxjnl-2017-211321
British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma
I. Woolhouse (2018)
10.1111/j.1440-1843.2011.01975.x
Asbestos use and asbestos‐related diseases in Asia: Past, present and future
G. Le (2011)
10.1016/S2213-2600(19)30139-0
Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial.
G. Scagliotti (2019)
10.21037/TLCR.2018.07.08
The use of patient-reported outcome measures (PROMs) in the management of malignant pleural mesothelioma: a descriptive literature survey
Youssef Ben Bouazza (2018)
10.1164/rccm.201210-1911OC
Pleural mesothelioma and occupational coexposure to asbestos, mineral wool, and silica.
A. Lacourt (2013)
10.2147/CLEP.S105396
Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)–Medicare investigation of treatment patterns and overall survival
J. Beebe-Dimmer (2016)
Non-asbestos-related malignant mesothelioma
JT Peterson (1984)
mesothelioma: SWOG S0509
SS Ramalingam (2011)
10.5694/mja11.10125
Increasing incidence of malignant mesothelioma after exposure to asbestos during home maintenance and renovation
Nola J. Olsen (2011)
10.1179/2049396714Y.0000000087
Asbestos-related occupational cancers compensated under the Spanish National Insurance System, 1978–2011
M. García-Gómez (2015)
10.1093/ejcts/ezr251
The new case for cervical mediastinoscopy in selection for radical surgery for malignant pleural mesothelioma.
A. Nakas (2012)
10.1016/j.chest.2016.12.004
Malignant Mesothelioma Biomarkers: From Discovery to Use in Clinical Practice for Diagnosis, Monitoring, Screening, and Treatment
J. Creaney (2017)
10.1016/S0140-6736(08)60727-8
Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial
M. Muers (2008)
10.1007/978-0-387-88441-7_26
[Pleural mesothelioma].
A. DE GASPERIS (1950)
10.1186/1750-9378-7-25
NLRP1 polymorphisms in patients with asbestos-associated mesothelioma
M. Girardelli (2012)
10.1093/AJCP/64.2.200
Diagnostic reliability of needle biopsy of the parietal pleura. A review of 272 biopsies.
D. V. Von Hoff (1975)
10.1136/oemed-2015-103105
A case–control study of mesothelioma in Minnesota iron ore (taconite) miners
Christine S Lambert (2015)
10.1084/jem.20140559
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
T. Voron (2015)
10.18632/oncotarget.14712
Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis
Dongxu Pei (2017)
advanced malignant pleural mesothelioma (MPM)
S Papa (2015)
10.1056/nejmoa051185
Asbestos exposure, pleural mesothelioma, and serum osteopontin levels.
H. Pass (2005)
10.1007/s12199-016-0508-4
Erratum to: High-risk mesothelioma relation to meteorological and geological condition and distance from naturally occurring asbestos
A. Abakay (2016)
10.1164/rccm.200907-1020OC
Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.
K. Hollevoet (2010)
10.1016/S1470-2045(14)71109-X
Carcinogenicity of fluoro-edenite, silicon carbide fibres and whiskers, and carbon nanotubes.
Y. Grosse (2014)
10.1016/j.jtho.2018.04.034
Revised Modified Response Evaluation Criteria in Solid Tumors for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1)
S. Armato (2018)
10.1148/RADIOLOGY.211.3.R99JN03657
Malignant pleural mesothelioma: US-guided histologic core-needle biopsy.
A. Heilo (1999)
10.1136/thx.2010.137018
Local anaesthetic thoracoscopy: British Thoracic Society pleural disease guideline 2010
N. Rahman (2010)
10.1016/j.lungcan.2015.05.014
Treatment patterns and survival analysis in 9014 patients with malignant pleural mesothelioma from Belgium, the Netherlands and England.
R. Damhuis (2015)
10.1016/j.canep.2013.12.002
Malignant pleural mesothelioma incidence and survival in the Republic of Ireland 1994-2009.
C. J. Jennings (2014)
10.1016/S1470-2045(13)70125-6
Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
W. Buikhuisen (2013)
10.1056/NEJMoa1112824
Immunologic correlates of the abscopal effect in a patient with melanoma.
M. Postow (2012)
10.1539/joh.17-0102-RA
Carcinogenicity of multi-walled carbon nanotubes: challenging issue on hazard assessment
S. Fukushima (2018)
10.1016/S1470-2045(15)70056-2
Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial.
L. Krug (2015)
10.1016/S0140-6736(07)60412-7
Ecological association between asbestos-related diseases and historical asbestos consumption: an international analysis
Ro-Ting Lin (2007)
10.1510/icvts.2010.255893
What is the best way to diagnose and stage malignant pleural mesothelioma?
I. Zahid (2011)
10.1016/j.lungcan.2013.05.006
A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma.
A. Nowak (2013)
10.1080/10408440802273156
A Meta-Analysis of Asbestos-Related Cancer Risk That Addresses Fiber Size and Mineral Type
D. Berman (2008)
10.1097/JTO.0b013e3182333df5
Brief Report: A Phase II Study of Sunitinib in Malignant Pleural Mesothelioma. The NCIC Clinical Trials Group
S. Laurie (2011)
10.1038/cdd.2017.95
Germline BAP1 mutations induce a Warburg effect
A. Bononi (2017)
Time trends and spatial patterns in the mesothelioma incidence in Slovenia
V Zadnik (1961)
first-line therapy in malignant pleural mesothelioma
JE Dowell (2013)
Almost half of women with malignant mesothelioma were exposed to asbestos at home through their husbands or sons.
M. Langhoff (2014)
10.1097/JTO.0b013e31820db377
Serial Measurements of Mesothelioma Serum Biomarkers in Asbestos-Exposed Individuals: A Prospective Longitudinal Cohort Study
K. Hollevoet (2011)
10.1093/ejcts/ezs648
Factors predicting poor survival after lung-sparing radical pleurectomy of IMIG stage III malignant pleural mesothelioma.
S. Boeluekbas (2013)
10.1289/ehp.0900868
Are Current or Future Mesothelioma Epidemics in Hong Kong the Tragic Legacy of Uncontrolled Use of Asbestos in the Past?
L. A. Tse (2010)
10.1016/j.jtho.2015.11.005
The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification.
F. Galateau-Sallé (2016)
10.1038/bjc.2012.44
First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial
Ó. Arrieta (2012)
10.1016/j.jtho.2016.06.024
A Phase II Study of PF‐03446962 in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207
P. Wheatley-Price (2016)
10.1097/COC.0b013e3181cae90e
Phase II Study of Gemcitabine Plus Docetaxel as Second-Line Treatment in Malignant Pleural Mesothelioma: A Single Institution Study
Ioannis S Tourkantonis (2011)
Latent period for malignant mesothelioma of occupational origin.
B. Lanphear (1992)
10.1510/mmcts.2019.023
Extended pleurectomy decortication for the treatment of malignant pleural mesothelioma.
A. Maat (2019)
10.1016/j.jtho.2016.09.124
The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma
V. Rusch (2016)
10.1002/1097-0142(19840901)54:5<951::AID-CNCR2820540536>3.0.CO;2-A
Non‐asbestos‐related malignant mesothelioma. A review
J. T. Peterson (1984)
10.1200/JCO.2016.71.2109
Differences in Treatment Effect Size Between Overall Survival and Progression-Free Survival in Immunotherapy Trials: A Meta-Epidemiologic Study of Trials With Results Posted at ClinicalTrials.gov.
A. Tan (2017)
10.1016/j.cancergen.2013.05.018
Further evidence for germline BAP1 mutations predisposing to melanoma and malignant mesothelioma.
M. Cheung (2013)
10.1016/j.canlet.2017.06.028
Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma.
M. Betti (2017)
10.1016/j.canlet.2016.05.011
CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma.
M. Betti (2016)
10.1016/j.ejcts.2008.03.034
Video-assisted cervical thoracoscopy: a novel approach for diagnosis, staging and pleurodesis of malignant pleural mesothelioma.
M. Chamberlain (2008)
10.1093/carcin/bgv097
Gene-asbestos interaction in malignant pleural mesothelioma susceptibility.
S. Tunesi (2015)
10.1111/j.1539-6924.2010.01411.x
Potency factors for risk assessment at Libby, Montana.
S. Moolgavkar (2010)
10.1378/chest.11-2727
High risk of malignant mesothelioma and pleural plaques in subjects born close to ophiolites.
Mehmet Bayram (2013)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar